HC Wainwright restated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $6.50 price target on the biopharmaceutical company’s stock.
Several other research firms also recently weighed in on NKTR. Piper Sandler began coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Nektar Therapeutics has an average rating of “Moderate Buy” and an average price target of $4.08.
View Our Latest Stock Report on NKTR
Nektar Therapeutics Stock Performance
Insider Activity at Nektar Therapeutics
In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the transaction, the insider now directly owns 326,904 shares of the company’s stock, valued at $307,289.76. The trade was a 13.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 155,575 shares of company stock valued at $149,878 in the last quarter. Insiders own 3.71% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. Victory Capital Management Inc. acquired a new position in Nektar Therapeutics during the 2nd quarter valued at about $29,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $34,000. Intech Investment Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $41,000. XTX Topco Ltd acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $46,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $61,000. 75.88% of the stock is owned by institutional investors and hedge funds.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
- Five stocks we like better than Nektar Therapeutics
- What is the Nikkei 225 index?
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- How to Find Undervalued Stocks
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.